PLCO
Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial
N = 78,216NCT00002540
- Population
- Women aged 55 to 74 years in the general US population
- Design
- Randomised screening trial at 10 US screening centres (November 1993 to July 2001). The intervention group was offered annual screening with CA-125 for 6 years and transvaginal ultrasound for 4 years; participants and their health care practitioners received the results and managed the evaluation of abnormal results. The usual care group received usual medical care. Follow-up was for a maximum of 13 years (median 12.4 years). This record covers the ovarian component only; the prostate and colorectal components are separate trial records.
- Primary endpoint
- Ovarian cancer mortality
- Arms
- Annual screening (experimental, n = 39,105): Annual CA-125 for 6 years and transvaginal ultrasound for 4 years
- Usual care (control, n = 39,111): Usual medical care without annual screening
- People
- Buys SS